All In Biotech

Drug Trial Radar · NCT00230178

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 12, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Apr 2004

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 30, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multi-center, open-label, parallel group study with three arms: * Rasburicase alone * Rasburicase followed by Allopurinol * Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three arms.

Conditions

  • Tumor Lysis Syndrome
  • Cancer
  • Hyperuricemia

Interventions

  • Rasburicase (SR29142)Drug

    30-min IV infusion

  • AllopurinolDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Uric Acid ResponderTime frame: Day 3 through Day 7

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Alta Bates Comprehensive Cancer Center

    Berkeley, California

  • UCLA Medical Center

    Los Angeles, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Florida Health Science Center at Jacksonville

    Jacksonville, Florida

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • New York Methodist Hospital

    Brooklyn, New York

  • Roswell Park Cancer Institute

    Buffalo, New York

  • University of Rochester Medical Center

    Rochester, New York

  • New York Medical College

    Valhalla, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Oregon Health and Sciences University

    Portland, Oregon

  • University of Pennsylvania Health Systems

    Philadelphia, Pennsylvania

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Mary Babb Randolph Cancer Center

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.